Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer

Background. Prostate cancer is one of the actual problems of modern oncology. The incidence of prostate cancer is steadily increasing despite of popularization of screening and early diagnostics. It is worth to highlight separately the castration-resistant prostate cancer which develops on the average 2 years after surgical or medicinal castration. For the patients with metastatic castration-resistant prostate cancer (mCRPC) the main purpose of treatment is increasing of overall survival while maintaining the quality of life. Currently there are several treatment options for mCRPC: chemotherapy, inhibitors of androgen receptor pathway, systemic alfa-radiotherapy, PARP-inhibitors for homologous recombination DNA repair deficiency. Using of several sequential lines of mCRPC therapy leads to maintaining the patients' quality of life and increasing its duration. Systemic alfa-radiotherapy is using since 2013 - the first is radium-223 which was approved by Food and Drug Administration according the results of the phase III trial ALSYMPCA. In Russian Federation radium-223 was approved in 2016. Objective: to evaluate the efficiency and safety of therapy with radium-223 as well as pain response at patients with mCRPC. Materials and methods. 67 patients were included in this analysis who received radium-223 therapy at Scientific Research Institute of Tomsk National Research Medical Center of Russian Academy of Sciences and Tomsk Regional Oncology Dispensary. Results and conclusion. Radium-223 has demonstrated its efficiency for mCRPC patients with good safety profile and positive pain response and maintaining the QoL.